MX356499B - Novel heteroarylamide derivatives having antiandrogenic properties. - Google Patents

Novel heteroarylamide derivatives having antiandrogenic properties.

Info

Publication number
MX356499B
MX356499B MX2014008524A MX2014008524A MX356499B MX 356499 B MX356499 B MX 356499B MX 2014008524 A MX2014008524 A MX 2014008524A MX 2014008524 A MX2014008524 A MX 2014008524A MX 356499 B MX356499 B MX 356499B
Authority
MX
Mexico
Prior art keywords
derivatives
antiandrogenic properties
novel
formula
heteroarylamide derivatives
Prior art date
Application number
MX2014008524A
Other languages
Spanish (es)
Other versions
MX2014008524A (en
Inventor
Ratilainen Jari
Koistinaho Milla
Muona Anu
Original Assignee
Medeia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeia Therapeutics Ltd filed Critical Medeia Therapeutics Ltd
Publication of MX2014008524A publication Critical patent/MX2014008524A/en
Publication of MX356499B publication Critical patent/MX356499B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to novel heteroarylamide derivatives having formula (I) and N-oxides, stereoisomers and pharmaceutically acceptable salts thereof, where RA, RB, R1 1, R', R", z and X are as defined in the claims. The arylamide derivatives of formula (I) have antiandrogenic properties. The invention also relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising them and to their preparation.
MX2014008524A 2012-01-13 2013-01-11 Novel heteroarylamide derivatives having antiandrogenic properties. MX356499B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20125039 2012-01-13
PCT/FI2013/050027 WO2013104830A1 (en) 2012-01-13 2013-01-11 Novel heteroarylamide derivatives having antiandrogenic properties

Publications (2)

Publication Number Publication Date
MX2014008524A MX2014008524A (en) 2014-08-21
MX356499B true MX356499B (en) 2018-05-30

Family

ID=47683784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008524A MX356499B (en) 2012-01-13 2013-01-11 Novel heteroarylamide derivatives having antiandrogenic properties.

Country Status (19)

Country Link
US (1) US9650382B2 (en)
EP (1) EP2802563B1 (en)
JP (1) JP6234376B2 (en)
KR (1) KR102058886B1 (en)
CN (1) CN104066717B (en)
AR (1) AR089702A1 (en)
AU (1) AU2013208847B2 (en)
BR (1) BR112014016896B1 (en)
CA (1) CA2861713C (en)
DK (1) DK2802563T3 (en)
EA (1) EA029007B1 (en)
ES (1) ES2640119T3 (en)
HK (1) HK1201838A1 (en)
MX (1) MX356499B (en)
NZ (1) NZ626715A (en)
PL (1) PL2802563T3 (en)
SG (1) SG11201404053RA (en)
TW (1) TWI635080B (en)
WO (1) WO2013104830A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (en) 1982-07-23 1987-08-15 Ici Plc AMIDE DERIVATIVES.
ES2331178T3 (en) 2001-12-13 2009-12-23 Sumitomo Chemical Company, Limited BICALUTAMIDE CRYSTALS AND METHOD FOR YOUR PRODUCTION.
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
WO2004041277A1 (en) * 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
MX2009000714A (en) 2006-07-19 2009-07-27 Osurf Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof.
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
DE102007058747A1 (en) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
ITBO20090078A1 (en) 2009-02-13 2010-08-14 Consiglio Nazionale Ricerche COMPOUNDS FOR TREATING TUMOR TO THE PROSTATE AND PROCEDURES FOR THEIR SYNTHESIS
US8741951B2 (en) 2009-04-10 2014-06-03 CNR—Consiglio Nazionale Delle Ricerche Non-steroidal compounds for androgen receptor modulation
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
FR2982261B1 (en) * 2011-11-04 2014-06-13 Galderma Res & Dev NOVEL AMIDES, AND THEIR PHARMACEUTICAL OR COSMETIC USE

Also Published As

Publication number Publication date
JP6234376B2 (en) 2017-11-22
CN104066717B (en) 2019-07-30
US9650382B2 (en) 2017-05-16
BR112014016896B1 (en) 2021-08-17
HK1201838A1 (en) 2015-09-11
DK2802563T3 (en) 2017-09-18
WO2013104830A1 (en) 2013-07-18
TW201332974A (en) 2013-08-16
NZ626715A (en) 2016-07-29
EA201491364A1 (en) 2014-11-28
KR20140117531A (en) 2014-10-07
US20150005308A1 (en) 2015-01-01
EP2802563A1 (en) 2014-11-19
CN104066717A (en) 2014-09-24
PL2802563T3 (en) 2017-11-30
ES2640119T3 (en) 2017-10-31
BR112014016896A8 (en) 2017-07-04
MX2014008524A (en) 2014-08-21
TWI635080B (en) 2018-09-11
AU2013208847B2 (en) 2017-08-31
JP2015504892A (en) 2015-02-16
AU2013208847A1 (en) 2014-08-14
CA2861713A1 (en) 2013-07-18
SG11201404053RA (en) 2014-10-30
EA029007B1 (en) 2018-01-31
CA2861713C (en) 2021-08-31
AR089702A1 (en) 2014-09-10
KR102058886B1 (en) 2019-12-24
EP2802563B1 (en) 2017-06-07
BR112014016896A2 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
MX2013000474A (en) Novel arylamide derivatives having antiandrogenic properties.
MX2020003055A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
PH12015501452A1 (en) Novel quinolone derivatives
MX2011011661A (en) Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750.
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX354102B (en) Benzimidazole-proline derivatives.
MY149731A (en) Compounds
GEP201606555B (en) Compounds and compositions for modulating egfr activity
GEP201706698B (en) Inhibitors of influenza viruses replication
NZ608116A (en) Triazine-oxadiazoles
MX2013003036A (en) Pyrazine derivatives as enac blockers.
UA104489C2 (en) Compounds for the treatment of dyslipidemia and related diseases
MX338551B (en) Novel fused pyridine compounds as casein kinase inhibitors.
WO2013004995A8 (en) Pyrimidinone compounds and their use
SG195106A1 (en) Trpv4 antagonists
MX2009013501A (en) Piperidine compounds and uses thereof.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2012008328A (en) Pyrazine derivatives.
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2014062838A3 (en) Pkm2 modulators and methods for their use
IN2012DN01292A (en)
TN2016000003A1 (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
WO2015002755A3 (en) Compounds for the treatment of malaria
TN2014000519A1 (en) Pyrimidinone derivatives as antimalarial agents
MX2013003736A (en) Novel gpr 119 agonists.

Legal Events

Date Code Title Description
FG Grant or registration